ASX - By Stock
|
RCE |
Re:
Ann: Safety Committee Approves High Dose of 4,000mg
|
|
zecs
|
7 |
2.6K |
10 |
26/04/24 |
26/04/24 |
ASX - By Stock
|
7
|
2.6K
|
10
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
zecs
|
44 |
15K |
12 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
44
|
15K
|
12
|
|
ASX - By Stock
|
EX1 |
Re:
Ann: Results of 2024 General Meeting
|
|
zecs
|
6 |
2.5K |
1 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
6
|
2.5K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
zecs
|
22 |
7.9K |
3 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
22
|
7.9K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
zecs
|
22 |
7.9K |
9 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
22
|
7.9K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
zecs
|
22 |
7.9K |
10 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
22
|
7.9K
|
10
|
|
ASX - By Stock
|
RCE |
Re:
RCE General Discussion Topics
|
|
zecs
|
51 |
25K |
6 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
51
|
25K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
zecs
|
48 |
14K |
4 |
24/03/24 |
24/03/24 |
ASX - By Stock
|
48
|
14K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
zecs
|
48 |
14K |
11 |
16/03/24 |
16/03/24 |
ASX - By Stock
|
48
|
14K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
zecs
|
48 |
14K |
10 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
48
|
14K
|
10
|
|
ASX - By Stock
|
EX1 |
Re:
Ann: EX1 signs binding agreement to acquire Tryp Therapeutics
|
|
zecs
|
4 |
2.5K |
0 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
4
|
2.5K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix 2023 Full Year Results and Investor Webcast/Call
|
|
zecs
|
130 |
43K |
4 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
130
|
43K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix 2023 Full Year Results and Investor Webcast/Call
|
|
zecs
|
130 |
43K |
4 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
130
|
43K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
[INTERVIEW] RCE teams with leading Indonesian biomed company for anti-infective push
|
|
zecs
|
25 |
7.5K |
3 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
25
|
7.5K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: AGM Presentation
|
|
zecs
|
7 |
2.7K |
5 |
08/11/23 |
08/11/23 |
ASX - By Stock
|
7
|
2.7K
|
5
|
|
ASX - By Stock
|
EX1 |
Re:
Ann: 2023 Notice of AGM, Proxy and Letter of Access
|
|
zecs
|
2 |
1.5K |
0 |
19/10/23 |
19/10/23 |
ASX - By Stock
|
2
|
1.5K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: US FDA grants Orphan Drug Designation for CRO-67
|
|
zecs
|
64 |
28K |
4 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
64
|
28K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: US FDA grants Orphan Drug Designation for CRO-67
|
|
zecs
|
64 |
28K |
2 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
64
|
28K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: US FDA grants Orphan Drug Designation for CRO-67
|
|
zecs
|
64 |
28K |
1 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
64
|
28K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: US FDA grants Orphan Drug Designation for CRO-67
|
|
zecs
|
64 |
28K |
7 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
64
|
28K
|
7
|
|
ASX - By Stock
|
EX1 |
Re:
When will we find out more?
|
|
zecs
|
13 |
6.6K |
0 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
13
|
6.6K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Pause in Trading
|
|
zecs
|
7 |
2.8K |
3 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
7
|
2.8K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Pause in Trading
|
|
zecs
|
7 |
2.8K |
5 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
7
|
2.8K
|
5
|
|
ASX - By Stock
|
EX1 |
Re:
Ann: Suspension from Quotation
|
|
zecs
|
10 |
5.4K |
6 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
10
|
5.4K
|
6
|
|
ASX - By Stock
|
EX1 |
Re:
Ann: Suspension from Quotation
|
|
zecs
|
10 |
5.4K |
4 |
02/10/23 |
02/10/23 |
ASX - By Stock
|
10
|
5.4K
|
4
|
|
ASX - By Stock
|
EX1 |
Re:
Ann: Suspension from Quotation
|
|
zecs
|
10 |
5.4K |
2 |
02/10/23 |
02/10/23 |
ASX - By Stock
|
10
|
5.4K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Entitlement Offer - Announcement of Results
|
|
zecs
|
13 |
5.5K |
3 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
13
|
5.5K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Entitlement Offer - Announcement of Results
|
|
zecs
|
13 |
5.5K |
2 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
13
|
5.5K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Latest CRO-67 data shows success in reducing cancer growth
|
|
zecs
|
7 |
3.0K |
2 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
7
|
3.0K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Latest CRO-67 data shows success in reducing cancer growth
|
|
zecs
|
7 |
3.0K |
3 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
7
|
3.0K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Completes Cohort Dosing UTI/Urosepsis Rapid Infusion Trial
|
|
zecs
|
16 |
5.9K |
5 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
16
|
5.9K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Change of Director's Interest Notice - FB
|
|
zecs
|
1 |
623 |
3 |
19/09/23 |
19/09/23 |
ASX - By Stock
|
1
|
623
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Trading Halt
|
|
zecs
|
66 |
17K |
10 |
09/09/23 |
09/09/23 |
ASX - By Stock
|
66
|
17K
|
10
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Trading Halt
|
|
zecs
|
66 |
17K |
8 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
66
|
17K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Trading Halt
|
|
zecs
|
66 |
17K |
5 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
66
|
17K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RECCE Trademark Registered - Vietnam
|
|
zecs
|
6 |
2.1K |
4 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
6
|
2.1K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RECCE Trademark Registered - Vietnam
|
|
zecs
|
6 |
2.1K |
13 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
6
|
2.1K
|
13
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Appendix 4E and Unaudited Preliminary Report
|
|
zecs
|
20 |
6.3K |
5 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
20
|
6.3K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Appendix 4E and Audited Financial Statements
|
|
zecs
|
5 |
2.3K |
2 |
04/09/23 |
04/09/23 |
ASX - By Stock
|
5
|
2.3K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Appendix 4E and Audited Financial Statements
|
|
zecs
|
5 |
2.3K |
1 |
04/09/23 |
04/09/23 |
ASX - By Stock
|
5
|
2.3K
|
1
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Annual Report for year ended 30 June 2023
|
|
zecs
|
2 |
1.1K |
0 |
28/08/23 |
28/08/23 |
ASX - By Stock
|
2
|
1.1K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: 1H 2023 Results Presentation
|
|
zecs
|
102 |
29K |
8 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
102
|
29K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I/II Burn Wound Infection Trial Stage 1 Complete
|
|
zecs
|
16 |
6.0K |
8 |
21/08/23 |
21/08/23 |
ASX - By Stock
|
16
|
6.0K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
zecs
|
124 |
40K |
3 |
17/08/23 |
17/08/23 |
ASX - By Stock
|
124
|
40K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
zecs
|
124 |
40K |
5 |
16/08/23 |
16/08/23 |
ASX - By Stock
|
124
|
40K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
zecs
|
124 |
40K |
3 |
11/08/23 |
11/08/23 |
ASX - By Stock
|
124
|
40K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
zecs
|
124 |
40K |
0 |
11/08/23 |
11/08/23 |
ASX - By Stock
|
124
|
40K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
zecs
|
124 |
40K |
0 |
10/08/23 |
10/08/23 |
ASX - By Stock
|
124
|
40K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
zecs
|
124 |
40K |
3 |
10/08/23 |
10/08/23 |
ASX - By Stock
|
124
|
40K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
zecs
|
124 |
40K |
3 |
10/08/23 |
10/08/23 |
ASX - By Stock
|
124
|
40K
|
3
|
|